Confo Therapeutics has presented preclinical data supporting the development of CFTX-2034, an investigational treatment for post-bariatric hypoglycaemia (PBH), at ENDO 2026.

The biotechnology company said the findings support continued development of the somatostatin receptor subtype 5 (SSTR5) agonistic antibody towards Phase 1 studies. PBH is a metabolic complication that can occur after bariatric surgery and currently has no approved treatments.

According to the company, CFTX-2034 is designed to selectively activate SSTR5, with the aim of reducing insulin and incretin secretion and helping restore glycaemic control in patients experiencing recurrent episodes of low blood sugar after weight loss surgery.

Data presented at the meeting showed the candidate suppressed insulin and GLP-1 secretion in a dose-dependent manner, improving glycaemic control without significantly inducing basal hyperglycaemia in preclinical models. The company also reported that CFTX-2034 did not activate related SSTR family members, suggesting a selective pharmacological profile, and demonstrated a long half-life that could support once-monthly subcutaneous dosing.

Christel Menet, chief scientific officer of Confo Therapeutics, said: “To our knowledge, Confo is the only company advancing a therapeutic candidate for PBH that targets SSTR5, a well-validated driver of disease biology.”

She added: “Importantly, leading clinical experts see the strong potential of CFTX-2034 to offer much needed glycemic control in PBH. In addition, CFTX-2034 is potentially compatible with GLP-1 agonists that are used by many patients for additional post-surgery weight management.”

PBH develops in some patients following bariatric surgery and is characterised by episodes of hypoglycaemia after eating. Symptoms can include impaired cognition, loss of consciousness and seizures, affecting quality of life and independence.

The presentation adds to Confo Therapeutics’ pipeline of GPCR-directed medicines targeting metabolic and endocrine diseases. The company said the ENDO 2026 findings support further IND-enabling studies for CFTX-2034.

Cedric Ververken, chief executive officer of Confo Therapeutics, said: “The data presented at ENDO 2026 support continued advancement of CFTX-2034 through IND-enabling studies and reinforce the strength of our pipeline in endocrine and metabolic diseases.”

As the programme remains in the preclinical stage, additional studies and clinical testing will be needed to establish the safety and efficacy of the candidate in humans.